TCRX advances solid-tumor TCR programs to IND-enabling stage
TCRX said two in vivo solid-tumor TCR therapies (PRAME, MAGE-A4) moved to IND-enabling stage with clinical trials planned for late 2027. Heme and autoimmune efforts are paused; financial runway extended into Q4 2027.
Two in vivo TCR therapies for solid tumors, PRAME and MAGE-A4, have advanced to the IND-enabling stage, with clinical trials planned for late 2027. The heme malignancy program has been paused after strong early results, pending partnerships, while autoimmune efforts have been halted for now. Financial runway has been extended into Q4 2027.